Pregnancy and Lactation Labeling Rule (PLLR): How to Read FDA Drug Safety Info
Dec, 5 2025
PLLR Drug Safety Decoder
Understand FDA pregnancy and lactation labeling with this interactive decoder. Enter a drug name to see what information you should look for in the new PLLR sections.
The old FDA pregnancy letter categories - A, B, C, D, X - are gone. They were simple, but they were misleading. A drug labeled "B" didn’t mean it was safe. It just meant there wasn’t enough human data. A "C" didn’t mean it was dangerous. It meant animal studies showed harm, but human studies were lacking. For pregnant women and their doctors, this system created more confusion than clarity. That’s why the FDA replaced it in 2014 with the Pregnancy and Lactation Labeling Rule (PLLR). Now, instead of a single letter, you get real, detailed information - written in plain language - about what a drug might do to a developing baby or a breastfeeding infant.
What the PLLR Actually Changed
Before the PLLR, drug labels had a single line under "Pregnancy" that said something like "Category C." That’s it. No context. No numbers. No explanation of when during pregnancy the risk was highest. No info on whether the drug passed into breast milk. Doctors had to guess. They’d look at the letter, flip through textbooks, or call a specialist - if they had time. The PLLR fixed that. It forced drugmakers to stop hiding behind vague letters and start giving real data. Now, every prescription drug label has three clear subsections under Section 8: Pregnancy, Lactation, and Females and Males of Reproductive Potential. Each one follows the same structure: Risk Summary, Clinical Considerations, and Data. This consistency makes it easier for providers to find what they need - fast.Decoding the Pregnancy Section (8.1)
The Pregnancy section isn’t just about birth defects. It’s about the full picture. Here’s what you’ll find:- Risk Summary: This isn’t a guess. It’s a clear statement: "Use of this drug during pregnancy may increase the risk of oligohydramnios, which can lead to fetal lung underdevelopment and limb contractures." Then it tells you how often this happened - "in 12% of exposed pregnancies" - and whether it was dose-dependent.
- Clinical Considerations: This is where practical advice lives. Should you stop the drug? Can you switch? What if you’re already pregnant? Does the drug affect labor? Will it cross the placenta? Does it cause preterm birth? This section answers those questions using real patient data.
- Data: This is the evidence. Animal studies. Human case reports. Registry data. Even if the human data is limited, it’s presented honestly. For example: "No controlled studies in pregnant women. Four case reports of neural tube defects in infants exposed during first trimester. No clear pattern observed."
One key improvement? The PLLR now requires drugmakers to mention the risks of not treating the illness. If a woman has bipolar disorder and stops her medication, what happens? If she has epilepsy and skips her seizure drug, what’s the risk to the baby? The PLLR forces this balance to be shown - not just the drug’s risks, but the risks of doing nothing.
Understanding the Lactation Section (8.2)
Breastfeeding and meds? The old system barely touched this. Now, the Lactation section gives you hard numbers. How much of the drug ends up in breast milk? Is it 0.5% of the mother’s dose? 2%? Is it even absorbed by the baby’s gut? The section answers:- Drug concentration in milk (often compared to maternal plasma levels)
- Estimated infant dose (in mg/kg/day)
- Known effects on the infant - sleepiness? poor weight gain? liver enzyme changes?
- Impact on milk supply - does the drug reduce production?
- Recommendations: "Breastfeeding is not recommended," or "Monitoring for drowsiness is advised," or "No adverse effects reported in over 100 exposed infants."
For example, a drug like sertraline might say: "Infant serum levels are undetectable in most cases. No adverse events reported in over 150 breastfed infants." That’s way more useful than "Lactation: Not studied."
Reproductive Potential Section (8.3) - Why It Matters
This section wasn’t part of the old system. But it’s critical. Many drugs affect fertility, or require pregnancy tests before starting. Others interact with birth control. The PLLR forces this info to be upfront.- Is a pregnancy test required before starting the drug?
- What kind of contraception is needed? And is it still effective if you’re on this drug? (Some drugs make birth control pills useless.)
- Is infertility a known side effect? Is it reversible?
- Are there recommendations for men? (Yes - some drugs affect sperm or are present in semen.)
Take isotretinoin (Accutane). The old label said "Category X." The PLLR label says: "Pregnancy must be excluded before treatment. Two forms of contraception required. Monthly pregnancy tests. Risk of severe birth defects. Men should not donate sperm during and for 1 month after treatment."
Why the Old Letter System Failed
The A, B, C, D, X system was broken because it assumed risk was binary. But pregnancy isn’t. A drug might be safe in the first trimester but dangerous in the third. Or it might be harmless to the baby but cause preeclampsia in the mother. The letter system couldn’t capture that.Worse, it created false safety. A drug with no human data got a "B" - so doctors assumed it was fine. But a drug with known risks got a "C" - so doctors avoided it, even if the benefit outweighed the risk. One study found that 70% of OB-GYNs misinterpreted Category C drugs as "unsafe" - even when the data showed the risk was low.
The PLLR fixes this by forcing transparency. If a drug has no data, it says so. If it has data showing a small risk, it says so. No hiding. No shortcuts.
What You’ll See in Real Labels
Look at the label for lisinopril, an ACE inhibitor. The PLLR section says: "Use during pregnancy, especially in the second and third trimesters, can cause fetal injury or death. Cases of oligohydramnios, fetal lung hypoplasia, skeletal deformations, and neonatal renal failure have been reported. Discontinue as soon as pregnancy is detected." That’s it. No guesswork.Now look at fluoxetine (Prozac). The label says: "Infant exposure through breast milk is low. No adverse events reported in over 200 breastfed infants. No effect on milk production. Breastfeeding is acceptable." Clear. Direct. Actionable.
What’s Missing - and What’s Being Fixed
The PLLR isn’t perfect. Some labels still lack data, especially for newer drugs. But here’s the big win: the rule now requires pregnancy exposure registries. These are real-world databases where doctors report outcomes when a pregnant woman takes a drug. Before, these were optional. Now they’re mandatory.For example, the Antiepileptic Drug Pregnancy Registry collects data from thousands of women. That’s how we now know that valproic acid carries a 10% risk of major birth defects - information that saved lives.
The FDA also requires labels to be updated when new data comes in. No more outdated warnings sitting on shelves for a decade. If a new study shows a drug causes heart defects, the label changes - fast.
How to Use This Info as a Patient
You don’t need to be a doctor to read this. If you’re pregnant or breastfeeding and prescribed a new drug, ask for the full prescribing information. Go to the FDA’s website and search the drug name. Look for Section 8. Read the Risk Summary. Ask: "Is this risk high or low? Is it proven? What if I don’t take it?" Don’t let a letter define your choice. Let the facts.Many women stop their meds out of fear. But sometimes, the risk of untreated depression, asthma, seizures, or high blood pressure is higher than the drug’s risk. The PLLR helps you and your provider weigh that.
What’s Next for PLLR?
The FDA is working with the European Medicines Agency (EMA) to align labeling standards. Right now, a drug labeled "safe for breastfeeding" in the U.S. might say "avoid" in Europe. That’s dangerous for travelers or expats. Harmonization is coming - slowly.Meanwhile, the PLLR is being expanded to include more biological products, vaccines, and even some over-the-counter drugs. The goal? No more guessing. Just clear, honest, usable information - for every woman who needs it.
What does "Category C" mean now under the PLLR?
"Category C" no longer exists. Under the Pregnancy and Lactation Labeling Rule (PLLR), drug labels no longer use letter categories. Instead, each medication has a detailed Risk Summary that explains known or potential risks based on human and animal data, clinical experience, and pharmacological activity. If a drug has limited human data but animal studies showed harm, the label will say so directly - for example, "Animal studies revealed fetal abnormalities, but human data are insufficient to determine risk." There is no simplified grade.
Can I trust the PLLR labels for breastfeeding safety?
Yes, PLLR labels are more reliable than older ones. They include specific measurements like drug concentration in breast milk, estimated infant dose, and documented effects on infants. For example, a label might state, "Infant exposure is less than 1% of maternal dose, with no reported adverse effects in over 100 cases." This level of detail allows providers to make informed decisions. Always check the Lactation section (8.2) - it’s the most accurate source available.
Does the PLLR apply to all medications?
The PLLR applies to all prescription drugs and biological products approved by the FDA since June 30, 2001. Older drugs were required to update their labels by December 2017 to remove the old A-B-C-D-X categories and replace them with PLLR sections. Over-the-counter drugs, supplements, and vaccines are not required to follow PLLR yet, though some manufacturers voluntarily include similar information.
Why is the "Females and Males of Reproductive Potential" section important?
This section addresses risks before pregnancy even occurs. Some drugs can cause birth defects even if taken before conception. Others interfere with fertility or make birth control ineffective. For example, isotretinoin requires pregnancy tests and two forms of contraception because it can cause severe defects even from short-term use. Men are also included because some drugs appear in semen and may affect a partner’s pregnancy. This section helps prevent exposure before it happens.
How often are PLLR labels updated?
Labels must be updated as soon as new safety data becomes available. Unlike the old system, where outdated information could stay on labels for years, the FDA now requires manufacturers to monitor post-market data and revise labeling promptly. If a new study shows a drug causes heart defects in infants, the label must be changed within months - not years. This ensures patients and providers always have the most current information.
Shayne Smith
December 6, 2025 AT 12:17Finally something that makes sense. I was so confused back in med school when they told me Category B was safe - turns out it just meant nobody bothered to study it. Now at least I can actually read what the drug does instead of guessing.
My OB-GYN showed me the new label for my anxiety med last trimester - real numbers, real risks, even how much gets into breast milk. Lifesaver.
Max Manoles
December 7, 2025 AT 05:33The PLLR is one of the few FDA reforms that actually improved clinical decision-making. The old letter system was a relic of 1970s risk-aversion masquerading as simplicity. What’s remarkable is how the new structure forces manufacturers to quantify uncertainty - not bury it.
Section 8.1’s requirement to state the risk of *not* treating maternal conditions is revolutionary. It flips the narrative from ‘drugs = bad’ to ‘balance matters.’ This isn’t just labeling - it’s ethical medicine.
Rashmi Gupta
December 8, 2025 AT 04:07They say the new system is better but let’s be real - most doctors still don’t read the full label. They glance at the ‘Breastfeeding: Acceptable’ line and call it a day. The data’s there, sure, but nobody uses it. This is just more paperwork dressed up as progress.
Kumar Shubhranshu
December 9, 2025 AT 22:27Karen Mitchell
December 11, 2025 AT 11:24This so-called improvement is just corporate appeasement. The FDA allowed pharmaceutical companies to bury dangerous drugs under layers of legalese while pretending transparency exists. Where’s the independent audit? Who verifies these ‘data’ sections? The same labs that profit from the drug’s sales?
And don’t get me started on ‘breastfeeding is acceptable’ - that’s not safety, that’s liability minimization.
olive ashley
December 12, 2025 AT 22:55They’re hiding something. Why does every label say ‘no adverse effects in over 100 infants’? That number is too clean. Too perfect. They’re cherry-picking data. The FDA’s been bought off by Big Pharma. Remember thalidomide? This is the same playbook - just with fancier formatting.
And why are men included? Because they’re testing sperm toxicity now? Next they’ll make men take pregnancy tests before getting prescriptions. This isn’t science. It’s control.
Ibrahim Yakubu
December 13, 2025 AT 20:18In Nigeria, we still use the old letter system because the new labels aren’t translated. Even if they were, most clinics don’t have internet to check FDA site. So this ‘improvement’ only helps rich countries. Meanwhile, pregnant women here are still told ‘avoid all meds’ - even for malaria or high blood pressure.
PLLR is great if you live in a hospital with Wi-Fi. For the rest of the world? Just noise.
Gwyneth Agnes
December 14, 2025 AT 06:19